News Archive - 2014

News Archive - 2014

Virus-fighting genes linked to mutations in cancer

Virus-fighting genes linked to mutations in cancer

Genetic evidence supports role of gene family in cancer development

Researchers have found a major piece of genetic evidence that confirms the role of a group of virus-fighting genes in cancer development.

Congenital heart disease gene found

Congenital heart disease gene found

Severe forms of congenital heart disease caused by variants of the NR2F2 gene

Researchers have explored the role of a master gene that controls the functioning of other genes involved in heart development. Variations in this gene - NR2F2 - are responsible for the development of severe forms of congenital heart disease.

The Sanger Institute honoured with Athena SWAN Bronze Award

The Sanger Institute honoured with Athena SWAN Bronze Award

The Sanger Institute is among the first research institutes in the UK to be recognised for commitment to advancing women's careers in science

The Wellcome Trust Sanger Institute is one of the first six research institutes in the UK to be recognised by the Equality Challenge Unit's Athena SWAN Charter, a scheme that recognises excellence in women's employment in science, technology, engineering, maths and medicine.

Genetic mutations warn of skin cancer risk

Genetic mutations warn of skin cancer risk

New high-risk cancer causing mutation identified for melanoma development

Researchers have discovered that mutations in a specific gene are responsible for a hereditary form of melanoma.

Where do you start when developing a new medicine?

Where do you start when developing a new medicine?

Novel scientific collaboration to use genomics and big data to drive drug discovery

A pioneering public-private research initiative between GSK, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute is to harness the power of 'big data' and genome sequencing to improve the success rate for discovering new medicines. The new Centre for Therapeutic Target Validation (CTTV) will aim to address a wide range of human diseases and will share its data openly in the interests of accelerating drug discovery.

Leukaemia caused by chromosome catastrophe

Leukaemia caused by chromosome catastrophe

Rare genetic event massively predisposes people to a form of leukaemia

Researchers have found that people born with a rare abnormality of their chromosomes have a 2,700-fold increased risk of a rare childhood leukaemia. In this abnormality, two specific chromosomes are fused together but become prone to catastrophic shattering.

Sanger Institute spinout Kymab announces therapeutic antibody discovery technology

Sanger Institute spinout Kymab announces therapeutic antibody discovery technology

Largest genetic engineering project to insert human genes

Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust Sanger Institute, announced today the publication in Nature Biotechnology of a paper describing its breakthrough therapeutic antibody discovery technology, Kymouse™.

Cancer therapy may be too targeted

Cancer therapy may be too targeted

Genetic landscape of rare cancer acts as a guide for future clinical trials

Researchers have identified two novel cancer genes that are associated with the development of a rare, highly aggressive, cancer of blood vessels. These genes may now act as markers for future treatments and explain why narrowly targeted therapies that are directed at just one target fail.

COSMIC celebrates its 10th anniversary

COSMIC celebrates its 10th anniversary

From simple spreadsheet to essential worldwide cancer research database in just one decade

In the space of just 10 years, the Catalogue of Somatic Mutations in Cancer, or COSMIC, has become the most comprehensive publicly accessible resource of genetic mutations that cause cancer. More than 6,000 researchers around the world make use of its data every day.

Genome Campus appoints Director of Scientific Conferences and Engagement

Genome Campus appoints Director of Scientific Conferences and Engagement

New role is part of 10-year strategy to create a genomic knowledge hub on the Genome Campus

The Wellcome Trust Genome Campus, which is home to the Wellcome Trust Sanger Institute and EMBL-European Bioinformatics Institute (EBI), has appointed a Director of Scientific Conferences and Engagement to further develop the campus as an internationally renowned centre for education and engagement in the area of genetics and genomics.

Pages